| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/16/2000 | CN1055469C Optically pure salts of pyridinylmethyl sulfinyl-1H-benzimidazole compounds, its preparing method and use |
| 08/16/2000 | CN1055468C Alkylaminoindane compounds process for preparing them and pharmaceutical compositions containing them,and use |
| 08/16/2000 | CN1055467C Taxoids compound, their preparation and pharmaceutical compositions containing them |
| 08/16/2000 | CN1055392C Drug composition for curing psoriasis and its medicinal use |
| 08/16/2000 | CN1055391C Use of substituted aromatic steroids control fertility and pharmaceutical composition thereof |
| 08/16/2000 | CN1055390C Process for preparing pharmaceutical composition having synergistic effect |
| 08/16/2000 | CN1055389C Composition and application against senile plaque formed on sin and/or slow death |
| 08/15/2000 | US6103936 Reacting aldehyde, sulfide, sulfone, or sulfoxide with formamide in presence of acid catalyst, and optionally a dehydrating agent |
| 08/15/2000 | US6103932 Useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, and neuropathological disorders |
| 08/15/2000 | US6103925 Muscle contraction inhibitors; modulator with selectivity for charybdotoxin-sensitive, calcium-dependent potassium channels |
| 08/15/2000 | US6103922 Anti-viral compounds |
| 08/15/2000 | US6103910 D-proline derivatives |
| 08/15/2000 | US6103909 Azole compounds endowed with antimycotic activity for human and veterinary use |
| 08/15/2000 | US6103907 Phenylalkylcarboxylic acid compounds and compositions for treating hyperglycemia |
| 08/15/2000 | US6103902 Carbamoylation process |
| 08/15/2000 | US6103897 Crystallization of amoxicillin salt from ethanolic solution containing amoxicillin and alkali or alkaline earth alcoholate or carboxylate; by-product inhibition |
| 08/15/2000 | US6103884 Glycosylated analogs of fusidic acid |
| 08/15/2000 | US6103883 Glycolipid mimics and methods of use thereof |
| 08/15/2000 | US6103874 Human KDEL receptor |
| 08/15/2000 | US6103771 Method of treating neuroma pain |
| 08/15/2000 | US6103766 Substituted or unsubstituted phenylsulfonamide-phenylamine derivatives useful for treating the disorders related to central nervous system |
| 08/15/2000 | US6103765 Methods for treating male erectile dysfunction |
| 08/15/2000 | US6103764 Method for increasing the aerobic capacity of muscle |
| 08/15/2000 | US6103762 A biaromatic compounds in which the aromatic nuclei are connected by a propynylene or allenylene divalent radical, useful as human or veterinary medicine or used in cosmetics or keratinization disorders |
| 08/15/2000 | US6103760 Aminotetralin derivative for the therapy of cardiovascular diseases |
| 08/15/2000 | US6103759 Halogen substituted carbamate compounds from 2-phenyl-1, 2-ethanediol |
| 08/15/2000 | US6103757 Administering a benzofuran derivative to the human suffering from arrhythmia |
| 08/15/2000 | US6103755 Foodstuff with prophylactic and/or healing effect and process for its production |
| 08/15/2000 | US6103752 Therapeutic heterocyclic compounds |
| 08/15/2000 | US6103748 Administering an amino acid protocol to the patient suffering from autoimmune disease, capable of being orally or gastrically nourished, comprises an essential amino acid, a non-essential amino acid, a lipid, vitamin and electrolyte |
| 08/15/2000 | US6103747 Substituted imidazole derivative used as antagonists against muscarinic acetylcholine receptor on smooth muscles, treats dysuria |
| 08/15/2000 | US6103746 Methods and compositions for the protection of mitochondria |
| 08/15/2000 | US6103743 Administering 2-amino 5,5-bis(substitutedphenyl)-4-pentenoic acid derivative a glycine transport inhibitor to a patient having a medical condition such as pain or spasticity |
| 08/15/2000 | US6103742 Administering to said patient a therapeutically effective amount of an insulin sensitivity enhancer in combination with a statin compound to treat diabetes |
| 08/15/2000 | US6103741 A solution of at least 0.75% w/v of levobupivacaine, measured as the free base; wherein the concentration of levobupivacaine is less than 2% w/v and is present atleast 90% enantiomeric excess with respect to dexbupivacaine |
| 08/15/2000 | US6103740 Methods for lowering platelet counts |
| 08/15/2000 | US6103739 Metalloproteinase inhibitors |
| 08/15/2000 | US6103738 Quinoline and quinazoline compounds useful in therapy |
| 08/15/2000 | US6103737 Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists |
| 08/15/2000 | US6103736 Showing an inhibitory action on gastric acid secretion and a protective action of gastric mucosa; 2-(hetero)aryl-3-aminoimidazo-(2,1-a)isoquinolines; antiulcer agents; |
| 08/15/2000 | US6103734 Based on administering certain chemicals or drugs so the detoxification procedure is carried out in <24 hour; fasting; alpha-adrenergic agents; gastro protecterants; opiate antagonist; sedation; naloxone test |
| 08/15/2000 | US6103733 Prevention of atherosclerosis and coronary heart disease; selective induction of hepatic cylochrome p450iiia (cyp3a) activity triphenylmethyl imidazoles or ppyridine substituted by a chlorine or fluorine |
| 08/15/2000 | US6103732 Endothelin receptor inhibitors; hypotensive agents, cardiotonic agents; acute myocardial infarct, pulmonary hypertension, raynaud's syndrome, atherosclerosis; asthma; cardiovascular disorders |
| 08/15/2000 | US6103731 Imidazol[1,5-c]quinazolines; a new class of GABA brain receptor |
| 08/15/2000 | US6103728 Modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders by inhibiting one or more abnormal tyrosine kinase activities; anticarcinogenic,-tumor, proliferative agents |
| 08/15/2000 | US6103725 High affinity to the dopamine d4 receptor; antagonists; antipsychotic agents, e.g. schizophrenia, with reduced side-effects; antipsychotic agents; anxiolytic and antiemetic agents; motoric functions, addiction, sleep, feeding |
| 08/15/2000 | US6103724 Exhibit mainly antipsychotic effects, e.g., schizophrenia, organic mental disorders, affective disorders, anxiety, personality disorders; neuroleptic activitiy; atypical antipsychotics, cognition activators, antidepressants; |
| 08/15/2000 | US6103723 Inhibitors of farnesyl-protein transferase |
| 08/15/2000 | US6103722 Ischemic preconditioning |
| 08/15/2000 | US6103721 Heteroaryl-substituted pyridazino quinoline compounds |
| 08/15/2000 | US6103720 Ketobenzamides as calpain inhibitors |
| 08/15/2000 | US6103719 Neurokinin-a- or neurokinin-b tachnkinin antagonistic properties; substance p antagonism; respiratory, gastrointestinal, nervous system, skin disorders; |
| 08/15/2000 | US6103718 Selective cyclic nucleotide phosphodiesterase (pde) inhibitors (specifically of type 4) which are effective bronchial therapeutics; bronchodilators; respiratory system disorders |
| 08/15/2000 | US6103716 Bactericides; administering my mouth to mammals and humans; prophylaxis; cattle, sheep, swine, poultry |
| 08/15/2000 | US6103715 Compounds that bind to the dopamine d4 receptor and their use as anxiolytic agents, treatment for schizophrenia, and drug screening; side effect reductioon |
| 08/15/2000 | US6103714 Oxidoreductase activity of manganic porphyrins |
| 08/15/2000 | US6103713 Therapeutic treatment for autoimmune diseases |
| 08/15/2000 | US6103712 Selective inhibitors of the beta isozyme of protein kinase c inhibits pulmonary vascular permeability, bronchial smooth muscle contractility, and airway hyperactivity, e.g. bisindolylmaleimides |
| 08/15/2000 | US6103711 Inhibitors of interleukin-1β converting enzyme |
| 08/15/2000 | US6103710 Glucocorticoid response elements |
| 08/15/2000 | US6103709 For treatment of bone diseases such as rickets, osteomalacia, osteoporosis, osteopenia, osteosclerosis, renal osteodystrophy; skin diseases, such as psoriasis; thyroid diseases, such as medullary carcinoma; brain diseases |
| 08/15/2000 | US6103705 Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound |
| 08/15/2000 | US6103704 Topically administering a therapeutically effective dosage of a formulation which comprises hyaluronic acid and an antiinflammatory or anticarcinogenic agent; treatment of diseases and conditions of the skin and exposed tissue |
| 08/15/2000 | US6103702 Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome |
| 08/15/2000 | US6103700 Fluoro labelled anthracyclinone and anthracycline derivatives |
| 08/15/2000 | US6103698 Useful in treating cancer in a mammal; in combination with paclitaxel and taxotere |
| 08/15/2000 | US6103694 Method of decreasing radiation of radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment |
| 08/15/2000 | US6103507 Protein used to raise an immunological response against a bacteria; bactericides |
| 08/15/2000 | US6103491 Methods and compositions for identifying morphogen analogs |
| 08/15/2000 | US6103487 Detecting modulators that suppress the activity of a transferases; anticarcinogenic agents |
| 08/15/2000 | US6103363 Glass-, ceramic- or vitroceramic-based substrate provided on at least part of at least one of its faces with a coating with a photocatalytic property containing at least partially crystalline titanium oxide |
| 08/15/2000 | US6103274 Pharmaceutical, orally applicable composition |
| 08/15/2000 | US6103273 Pharmaceutical composition comprising starch, a compound comprising boron, a compound comprising zinc, and water, and a method of using same to encourage hair growth |
| 08/15/2000 | US6103268 Orally administering osmotic colonic evacuant comprising picosulfate laxative in solid form, together with specified volume of diluent |
| 08/15/2000 | US6103264 Process for preparing a controlled release composition |
| 08/15/2000 | US6103262 Composition capable of delivering acceptable bioavailability for up to twenty-four hours |
| 08/15/2000 | US6103261 Opioid formulations having extended controlled release |
| 08/15/2000 | US6103260 Antifoam oral solid dosage form preparations |
| 08/15/2000 | US6103258 Administering a therapeutic dose of an opioid analgesic agonist and an amount of nalmefene to enhance the effects of dopamine-increasing opioid receptors and reduce the effects of dopamine-decreasing opioid receptors. |
| 08/15/2000 | US6103254 Methods for sterilizing male mammals |
| 08/15/2000 | US6103253 Films which can be produced thereof are pressure-sensitive adhesive, water-insoluble, and at least partially biodegradable; cellulose derivative or a homopolymer or a copolymer of hydroxybutanoic acid or hydroxyvaleric acid. |
| 08/15/2000 | US6103247 Composition containing a non-photocatalytic metal oxide and tocopherol, its use in the cosmetics and/or dermatological field and processes employing it |
| 08/15/2000 | US6103225 Methods of aquaculture by feeding larval shrimp Thraustochytrium and/or Schizochytrium microflora |
| 08/15/2000 | US6103220 Lysine decarboxylase inhibitors for the prevention and treatment of periodontal disease |
| 08/15/2000 | US6102254 Pharmaceutical compositions in semisolid form and a device for administration thereof |
| 08/15/2000 | CA2287056C Orally administrable solid ribavirin dosage forms and process for making them |
| 08/15/2000 | CA2202280C Sugar modified nucleosides and their use for synthesis of oligonucleotides |
| 08/15/2000 | CA2148671C Stable crystalline (6s)-and (6r)-tetrahydrofolic acid |
| 08/15/2000 | CA2136553C 7-(2-aminoethyl)-benzothiazolones |
| 08/15/2000 | CA2105385C Treatment of cognitive disorders |
| 08/15/2000 | CA2062735C Novel methylenebisphosphonic acid derivatives |
| 08/15/2000 | CA2046883C Heterocyclic derivatives, method for preparing same, and their therapeutic applications |
| 08/15/2000 | CA1341087C Medicaments including hyaluronic acid as a drug delivery system |
| 08/10/2000 | WO2000046391A2 Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof |
| 08/10/2000 | WO2000046389A1 Process for the preparation of pseudomonic acid a antibiotic by microbiological method |
| 08/10/2000 | WO2000046386A2 Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
| 08/10/2000 | WO2000046385A1 Gene repair involving in vivo excision of targeting dna |
| 08/10/2000 | WO2000046253A1 Process for the production of multiple cross-linked hyaluronic acid derivatives |
| 08/10/2000 | WO2000046252A1 Process for cross-linking hyaluronic acid to polymers |
| 08/10/2000 | WO2000046246A1 Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease |